Center-Authored Papers

Filters: Author is Scott, Bart L  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
No Keywords
Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ.  2008.  Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.. Blood. 112(7):2681-6. Abstract
2008
Scott BL, Park JY, Deeg HJ, Marr KA, Boeckh MJ, Chauncey TR, Appelbaum FR, Storb R, Storer BE.  2008.  Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(7):799-806. Abstract
Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM et al..  2008.  Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(2):246-55. Abstract
Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ.  2008.  Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.. Blood. 112(7):2681-6. Abstract
2010
Scott BL, Ramakrishnan A, Storer BE, Becker PS, Petersdorf SH, Estey EH, Deeg HJ.  2010.  Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.. British journal of haematology. 148(6):944-7. Abstract
Scott BL, Ramakrishnan A, Fosdal M, Storer BE, Becker P, Petersdorf SH, Deeg HJ.  2010.  Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study.. British journal of haematology. 149(5):706-10. Abstract
Scott BL, Deeg HJ.  2010.  Myelodysplastic syndromes.. Annual review of medicine. 61:345-58. Abstract
2011
Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney K, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE et al..  2011.  Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(3):341-50. Abstract
Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, Loeb KR, Martin PJ, Pagel JM, Radich JP et al..  2011.  Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(6):908-15. Abstract
2012
Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL.  2012.  Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(8):1211-8. Abstract
Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J, Sandmaier BM, Myerson D, Chauncey TR, Storb R et al..  2012.  The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.. Blood. 119(11):2657-2664. Abstract
Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP et al..  2012.  Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.. Blood. 120(7):1398-408. Abstract
Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP et al..  2012.  Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.. Blood. 120(7):1398-408. Abstract
Venner CP, Wegrzyn Woltosz J, Nevill TJ, Deeg HJ, Caceres G, Platzbecker U, Scott BL, Sokol L, Sung S, List AF et al..  2013.  Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome.. Haematologica. 98(3):409-13. Abstract
Platzbecker U, Schetelig J, Finke J, Trenschel R, Scott BL, Kobbe G, Schaefer-Eckart K, Bornhäuser M, Itzykson R, Germing U et al..  2012.  Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(9):1415-21. Abstract
2013
Walter RB, Medeiros BC, Gardner KM, Orlowski KF, Gallegos L, Scott BL, Hendrie PC, Estey EH.  2013.  Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase 1/2 study.. Haematologica. Abstract
Vaughn JE, Scott BL, Deeg HJ.  2013.  Transplantation for myelodysplastic syndromes 2013.. Current opinion in hematology. 20(6):494-500. Abstract
Venner CP, Wegrzyn Woltosz J, Nevill TJ, Deeg HJ, Caceres G, Platzbecker U, Scott BL, Sokol L, Sung S, List AF et al..  2013.  Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome.. Haematologica. 98(3):409-13. Abstract
Gerds AT, Walter MJ, Scott BL.  2013.  Emerging importance of mutational analysis in myelodysplastic syndrome and acute myelogenous leukemia.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(1 Suppl):S33-7.
Laille E, Savona MR, Scott BL, Boyd TE, Dong Q, Skikne B.  2013.  Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies.. Journal of clinical pharmacology. Abstract
2014
Lionberger JM, Pagel JM, Sandhu VK, Xie H, Shadman M, Mawad R, Boehm A, Dean C, Shannon-Dorcy K, Scott BL et al..  2014.  Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design.. British journal of haematology. 166(3):375-81. Abstract
Adolescent
Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney K, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE et al..  2011.  Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(3):341-50. Abstract
Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP et al..  2012.  Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.. Blood. 120(7):1398-408. Abstract
Scott BL, Park JY, Deeg HJ, Marr KA, Boeckh MJ, Chauncey TR, Appelbaum FR, Storb R, Storer BE.  2008.  Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(7):799-806. Abstract
Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP et al..  2012.  Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.. Blood. 120(7):1398-408. Abstract